Denali Therapeutics Inc (DNLI)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$20.45
Buy
$24.00
$-0.04 (-0.19%)
Prices updated at 20 Dec 2024, 22:03 EST
| Prices minimum 15 mins delay
Prices in USD
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2022 | 2023 |
|---|---|---|
| 108m | 331m | |
| - | - | |
| -341m | -197m | |
| -314.16 | -59.51 | |
| -326m | -145m | |
| -330m | -180m | |
| Sales, General and administrative | 90m | 103m |
| Interest expenses | - | - |
| Provision for income taxes | 21,000 | 30,000 |
| Operating expenses | 449m | 527m |
| Income before taxes | -326m | -145m |
| Net income available to common shareholders | -326m | -145m |
| -2.6 | -1.06 | |
| Net interest income | 15m | 52m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -2.6 | -1.06 |
| Free cash flow per share | -2.0644 | -2.5546 |
| Book value/share | 5.967 | 8.0813 |
| Debt equity ratio | 0.050873 | 0.04363 |
Balance sheet
Year | 2022 | 2023 |
|---|---|---|
| Current assets | 1,372m | 1,064m |
| Current liabilities | 364m | 78m |
| Total capital | 1,042m | 1,031m |
| Total debt | 60m | 52m |
| Total equity | 1,042m | 1,031m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 1,460m | 1,154m |
| Total liabilities | - | - |
| Cash and cash equivalents | 218m | 127m |
| Common stock | 136m | 138m |
Cash flow
Year | 2022 | 2023 |
|---|---|---|
| Cash at beginning of period | 295m | 220m |
| Cash dividends paid | - | - |
| -263m | -371m | |
| Investments (gains) losses | -141m | 249m |
| 220m | 129m | |
| Net income | - | - |
| -245m | -358m | |
| -18m | -13m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
